News
OTLC
0.012
-2.40%
-0.000
Weekly Report: what happened at OTLC last week (1109-1113)?
Weekly Report · 6d ago
Weekly Report: what happened at OTLC last week (1102-1106)?
Weekly Report · 11/09 09:09
3 Hot Stocks with Recent Insider Buying
TipRanks · 11/02 12:58
Weekly Report: what happened at OTLC last week (1026-1030)?
Weekly Report · 11/02 09:09
Oncotelic showcases AI-driven oncology discovery framework
TipRanks · 10/26 13:30
Weekly Report: what happened at OTLC last week (1019-1023)?
Weekly Report · 10/26 09:09
Weekly Report: what happened at OTLC last week (1012-1016)?
Weekly Report · 10/19 09:09
Oncotelic highlights PDAOAI platform and BIO REBOOT initiative
TipRanks · 10/13 13:33
Weekly Report: what happened at OTLC last week (1005-1009)?
Weekly Report · 10/12 09:10
Weekly Report: what happened at OTLC last week (0928-1002)?
Weekly Report · 10/05 09:10
Weekly Report: what happened at OTLC last week (0921-0925)?
Weekly Report · 09/28 09:09
Weekly Report: what happened at OTLC last week (0914-0918)?
Weekly Report · 09/21 09:09
Weekly Report: what happened at OTLC last week (0907-0911)?
Weekly Report · 09/14 09:10
Weekly Report: what happened at OTLC last week (0831-0904)?
Weekly Report · 09/07 09:09
Weekly Report: what happened at OTLC last week (0824-0828)?
Weekly Report · 08/31 09:10
Weekly Report: what happened at OTLC last week (0817-0821)?
Weekly Report · 08/24 09:10
Weekly Report: what happened at OTLC last week (0810-0814)?
Weekly Report · 08/17 09:10
Weekly Report: what happened at OTLC last week (0803-0807)?
Weekly Report · 08/10 09:10
Oncotelic Announces New Convertible Note Financing Agreement
TipRanks · 08/04 21:06
Weekly Report: what happened at OTLC last week (0727-0731)?
Weekly Report · 08/03 09:10
More
Webull provides a variety of real-time OTLC stock news. You can receive the latest news about Oncotelic Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About OTLC
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of orphan oncology indications, developing antisense and small-molecule injectable drugs for the treatment of cancer. The Company has three primary drugs and AI technology programs: AL-101 - Intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson’s Disease (PD), erectile dysfunction (ED) and female sexual dysfunction (FSD); CA4P- a vascular disrupting agent (VDA) - in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma; Oxi4503- a second generation VDA - for the treatment of liquid tumors with focus on childhood leukemia; OT-101 - an antisense against TGF-b2-for the treatment of various cancers and for the treatment of various viruses, and Artemisinin-a natural derivative from an Asian herb Artemisia Annua.